Special Issue "Emerging Trends in COVID-19 and Heart Failure"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 12021
Over the past few years, the modern world is faced with a tremendous challenge in the form of coronavirus disease (COVID-19), caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). The analyses conducted so far have shown that patients with preexisting cardiovascular disease, heart failure in particular, suffer more frequently, have an adverse course and high risk of death in the course of COVID-19. There are several research hypotheses describing the pathomechanism of these processes, pointing to underlying structural cardiac and vascular dysfunction, impaired capacity to endure inflammation, neurohormonal imbalance, myocardial damage related to virus infiltration and cytokine storm. There are also different degrees of severity, a variety in cardiac manifestations, abnormalities in laboratory parameters and additional tests. Moreover, the impact of therapies and vaccination plays an important role. There is a need to further study of patients with COVID-19 and heart failure. The aim is not only to get to know the interaction between these two syndromes but also to better understand the pathophysiology of both COVID-19 and heart failure. Currently SARS-CoV-2 evolves, changes its characteristics and invariably is inherent in population. We invite you to submit high level mechanistic and clinical research regarding COVID-19 and heart failure to the Special Issue of Biomedicines.
Dr. Mateusz Sokolski
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.